Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase 1/2 Completed
60 enrolled
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
Phase 1/2 Completed
116 enrolled 31 charts
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Phase 1/2 Completed
36 enrolled
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Phase 1/2 Completed
160 enrolled 21 charts
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
Phase 1/2 Completed
65 enrolled 21 charts
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase 1/2 Completed
46 enrolled
MSC11FCD-GBM
Phase 1/2 Completed
10 enrolled
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
125 enrolled 12 charts
RTOG 0913
Phase 1/2 Completed
279 enrolled 14 charts
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Phase 1/2 Completed
121 enrolled 27 charts
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Phase 1/2 Completed
79 enrolled 17 charts
Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
Phase 1/2 Completed
158 enrolled
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Phase 1/2 Completed
72 enrolled 19 charts
Sirolimus in Treating Patients With Glioblastoma Multiforme
Phase 1/2 Completed
13 enrolled
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase 1/2 Completed
122 enrolled 11 charts
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
217 enrolled 12 charts
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Phase 1/2 Completed
25 enrolled 14 charts
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
92 enrolled 18 charts
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
Phase 1/2 Completed
35 enrolled 13 charts
Zactima
Phase 1/2 Completed
119 enrolled 15 charts
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Phase 1/2 Completed
30 enrolled 11 charts
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase 1/2 Completed
92 enrolled 24 charts
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
Phase 1/2 Completed
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase 1/2 Completed
105 enrolled
Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
Phase 1/2 Completed
136 enrolled
CCI-779 in Treating Patients With Malignant Glioma
Phase 1/2 Completed
49 enrolled
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 1/2 Completed
116 enrolled 17 charts
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 1/2 Completed
118 enrolled 10 charts
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
Phase 1/2 Completed
57 enrolled 18 charts
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase 1/2 Completed
136 enrolled 27 charts
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
Phase 1/2 Completed
257 enrolled 16 charts
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
Phase 1/2 Completed
60 enrolled 22 charts
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
Phase 1/2 Completed
50 enrolled 6 charts
Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase 1/2 Completed
58 enrolled
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
112 enrolled 14 charts
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
Phase 1/2 Completed
61 enrolled 8 charts
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase 1/2 Completed
40 enrolled
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Phase 1/2 Completed
69 enrolled 12 charts
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
Phase 1/2 Completed
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers
Phase 1/2 Completed
Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 1/2 Completed
24 enrolled
Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain
Phase 1/2 Completed
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
Phase 1/2 Completed
Immunotoxin Therapy in Treating Patients With Malignant Glioma
Phase 1/2 Completed
Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors
Phase 1/2 Completed
Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase 1/2 Completed
Procarbazine in Treating Patients With Recurrent Brain Tumor
Phase 1/2 Completed
COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors
Phase 1/2 Completed
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase 1/2 Completed
48 enrolled
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
Phase 1/2 Completed
16 enrolled